Unlike closely related GPCRs, protease-activated receptors (PAR1, PAR2, PAR3, and PAR4) have 20 a predicted signal peptide at their N-terminus, which is encoded by a separate exon, suggesting that the 21 signal peptides of PARs may serve an important and unique function, specific for PARs. In this report, we
Introduction

37
G-protein coupled receptors (GPCRs) are a class of 7 transmembrane domain cell surface receptors 38 and consist of the largest receptor family in mammals and other organisms. They are involved in the signal 39 transduction of almost every system in human physiology, including the sensory, metabolic, endocrine, 40 immune, and the nervous systems. Unlike many other cell surface receptors that have a classical signal 41 peptide to lead the proteins to cells surface, the majority of GPCRs (>90%) do not have a signal peptide 42 (1) . In general, class B receptors such as the secretin receptor (2), corticotropin-releasing hormone (CRH) 43 receptors (3), the Glucagon receptor (4), and Glucagon-like peptide receptors (5) and the class C GPCRs, 44 such as metabotropic glutamate receptors (6), GABA receptors (7), and adhesion GPCRs (8),which have 45 relatively large N-terminal extracellular domains are more likely to have signal peptides than class A 46 receptors (Fig 1A) . It is hypothesized that the presence of the signal peptide helps the large hydrophilic Nterminus to cross the plasma membrane. Most class A GPCRs do not have classical signal peptides. It is 48 believed that the first transmembrane domain of these class A GPCRs serves as a signal anchor sequence 49 allowing these receptors to translocate to the cell membrane after translation and assembly in the 50 endoplasmic reticulum (ER) (9). Protease-activated receptors (PARs), including PAR1, PAR2, PAR3, and 51 PAR4 belong to class A GPCR receptor sub-family (10). Homology-wise, they are very closely related to 52 cysteinyl leukotriene receptors (CYSLT), niacin receptors (GPR109), lactic acid receptor (GPR81), and the 53 succinate receptor (GPR91). Unlike their closest neighbors (Fig 1B) , which do not possess a signal peptide, 54 all PARs have a predicted signal peptide at their N-termini (Fig 1C) . Genomic analyses show, in contrast 55 to their closest neighbors that are all encoded by single exon genes, PARs have an additional exon encoding 56 only the signal peptides (Fig 1C) , suggesting that these signal peptides may play a specific role for PARs.
57
In this report, we used PAR2 to study the importance of the signal peptide in PAR receptor function and 58 localization. 
150
To measure intracellular IgG-Fc protein, one day after transfection, cells were trypsinized and 151 seeded in 96-well culture plates (30,000 cell/well) and grown in DMEM supplemented with 10% FCS, 1 152 mM pyruvate, 20 mM HEPES. Three days after transfection, the media were removed, and cells were 153 washed using PBS, and then fixed by 10% formaldehyde in PBS at RT for 15 min. The cells were penetrated 154 using 1% Triton-X-100 at RT for 10 min and blocked using 3% no-fat milk in PBST for 30 min at RT. The 155 cells were then incubated using HRP-conjugated goat-anti-human IgG-Fc antibody and the plate was 156 developed and read as described above.
157
Immuno-fluorescent staining of intracellular IgG-Fc 158 COS7 cells were transfected with various IgG-Fc expression constructs. One day after transfection, 159 cells were trypsinized and seeded in a 4-well cell culture chamber slides (Stellar Scientific, Baltimore, MD)
160
(60,000 cells/well). Three days after transfection, the media were removed, and cells were washed using 161 PBS, and then fixed by 10% formaldehyde in PBS at RT for 15 min. The cells were penetrated using 1%
162
Triton-X-100 at RT for 10 min and blocked using 3% no-fat milk in PBST for 30 min at RT. The cells were 
183
Protease inhibitor treatment of cells recombinantly expressing PAR2 receptors 184
The wild type and various mutant PAR2 variant expression constructs were transiently transfected 185 into HEK293 cells with par1 & par2 genes knocked-out. 24 hrs after transfection, cells were treated for 12 186 hrs with a protease inhibitor cocktail including 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride 187 (AEBSF, 500 uM), Leupeptin (50 uM), aprotinin (50 uM).
188
Measurement of the total and cell surface expression of PAR2 by ELISA
189
ELISA was used to measure the total and cell surface PAR2 protein expression. The wild type and 190 different mutant PAR2 variants were transiently expressed in HEK293 cells with the endogenous PAR1
191
and PAR2 knocked-out. The cells were transfected in 10 cm cell culture dishes and, 24 hr after transfection,
193
To measure the total PAR2 expression, the fixed cells were penetrated using 1% triton-X-100, and blocked 194 with 3% no-fat milk, and then incubated with a monoclonal antibody [3 g/ml, mouse anti-human PAR2
195
(BioLegand, San Diego, CA)], which recognizes the N-terminal region (amino acid residues 37-62) of the 196 human PAR2, at 4 o C overnight. The plate was washed with cold PBS 3 times and then incubated using a 197 HRP-conjugated goat-anti-mouse IgG secondary antibody (30 ng/ml, Pierce) at RT for 1 hr. The plate was 198 washed again using PBS and developed using an ELISA developing kit as described above. To measure 199 the cell surface PAR2 expression, the ELISA assays were performed in the same manner as the total PAR2
200 measurement without using triton-X-100 as the cell penetrating agent.
201
Measurement of the total expression and cellular localization of PAR2-GFP fusion proteins
202 GFP fusion proteins of PAR2 wild type and various mutants were transiently expressed in 96-well 203 poly-D-lysine plates in HEK293 cells with the endogenous PAR1 and PAR2 knocked-out as described 214 hydrophobic amino acid residues. Its known function is to help a secreted or a cell surface protein to target 215 the ER during protein translation and cross the plasma membrane. PAR2 has a predicted signal peptide 216 sequence at its N-terminus and we hypothesized that it may function as a classical signal peptide. To address 217 this, we devised a few expression constructs (Fig 2A) to test whether the signal peptide of PAR2 enables 218 the secretion of human IgG-Fc fragment (which lacks a signal peptide) into the cell culture medium. IgG-
219
Fc was used since it was easy to detect using ELISA or immune-staining. When recombinantly expressed 220 in mammalian cells, without a signal peptide, IgG-Fc is only expressed intracellularly. In contrast, with a 221 signal peptide, IgG-Fc can be secreted into the cells culture medium. One IgG-Fc construct contained the 222 N-terminus of PAR2 with its signal peptide and another with the PAR2 N-terminus in which its signal 223 peptide was deleted. As positive controls, constructs with an insulin signal peptide (a secreted protein signal 224 peptide) or an insulin receptor signal peptide (a cell surface receptor signal peptide) fused to human IgG-
225
Fc were also used in the experiment. We used immuno-staining ( Fig 2B) and ELISA (Fig 2C) to detect and 228 showed that fusing the N-terminus of PAR2 with its signal peptide to the human IgG-Fc, effectively led to 229 the secretion of IgG-Fc to the medium, thus functioning similarly to that of the insulin signal peptide or the 230 insulin receptor signal peptide (Fig 2D) . In contrast, fusing the PAR2 N-terminus without its signal peptide 231 failed to lead to the secretion of IgG-Fc into the medium. It has been reported that for the CRF2(a) receptor, the signal peptide may not be cleaved from the 248 mature proteins following membrane insertion (14). To determine if this is the case for the PAR2 signal 249 peptide, we examined whether the signal peptide of PAR2 is cleaved from the mature IgG-Fc protein with 250 the PAR2 N-terminus following secretion. The conditioned medium from the COS7 cells transfected with 251 the expression construct for PAR2 N-terminus fused to IgG-Fc (Fig 2A) was collected. Secreted PAR2-
252
IgG-Fc fusion protein was affinity purified, glycosylation moieties removed, and then analyzed by mass 253 spectrometric (MS) protein sequencing. Our results showed that the most N-terminal sequence that matches 254 PAR2 sequence is TIQGTNR (Fig 3) , suggesting that the signal peptide has been cleaved following the 255 protein secretion, with the cleavage site being between residues Gly 24 and Thr 25 . Interestingly, a variant 256 sequence TIQGTDR was also observed. This sequence differs from TIQGTNR by one residue (from N to 257 D). Since the residue Asn 30 is a part of a NRS sequence (a N-linked glycosylation site, Fig 3) and
258 glycosylated Asn residues are converted to Asp after de-glycosylation by PNGase-F, our results suggest 259 that at least part of the expressed protein is glycosylated at this N-linked glycosylation site. To evaluate the receptor localization and function of recombinant PAR2, it is essential to have a commonly used mammalian cells for recombinant expression, including HEK293, CHO-K1, and COS7
273 cells and found that all three cell lines express relatively high PAR1 and PAR2 mRNA (Fig 4A) . In addition,
274
in functional assays, they all responded to PAR1 and PAR2 ligands (thrombin and trypsin, respectively) 275 (Fig 4B-D) . Since the presence of naturally expressed PAR1 and PAR2 in these host cells would complicate 276 the characterization of the recombinantly expressed PAR2, we created a HEK293 cell line (which does not 277 express PAR3 and PAR4) with both par1 and par2 genes knocked-out by CRISPR/cas9 (Fig 4E) .
278
Pharmacological characterization of this cells line demonstrated that the loss of both par1 & par2 led to a 279 lack of responses to PAR1 ligand (thrombin) or PAR2 ligand (trypsin) stimulation (Fig 4F) . These cells 280 were then used to study expression and localization of recombinant PAR2. 
295
Characterization of par1 & par2 knock-out HEK293 cells. FLIPR assays were used to characterize receptor activation as indicated.
296
Wild type HEK293 cells were used as the positive control. The assays were performed in triplicates at each data point and mean ± 297 sd are shown. peptide (PAR2-IRSP) (Fig 5A) . Pharmacological characterization of the modified receptors using FLIPR 305 assay (Fig 5B, C) showed that the recombinantly expressed PAR2 responds to trypsin (EC 50 = 1.5 nM) and mechanism, combined with the fact that signal peptide-less PAR2 has a poor response to ligand stimulation, led us to speculate that the necessity of the signal peptide for PAR2 may be related to the presence of 337 tethered ligand. We made a signal peptide-less PAR2 mutant with a further deletion to the region of the 338 tethered ligand (PAR2∆SP∆L) (Fig 6A) . This mutant receptor lacks the signal peptide and the tethered 339 ligand sequence (SLIGKV) and is not activated by trypsin, however it can be fully activated by the synthetic 340 agonist peptide PAR2-AP similarly to the wild type PAR2 receptor in the FLIPR assay (Fig 6B) . This
341
suggests that further deletion of the tethered ligand sequence (SLIGKV) restored functional cell surface 342 expression of PAR2 without the signal peptide. The results also suggest that, without a signal peptide,
343
PAR2 may be susceptible to unintended intracellular protease activation, leading to poor functional cell 344 surface expression. N-terminus (with sequence SLIGKV---), which serves as a tethered ligand to activate the receptor.
361
Mutating Arg 36 to Ala prevents the trypsin cleavage at this position, and therefore blocks trypsin-362 mediated receptor activation. We made a mutation at the Arg 36 position on PAR2 without the 363 signal peptide (PAR2∆SP(R36A)) and tested whether this mutation changes the level of functional 364 receptor expression. In parallel, we also made the same mutation on the full length PAR2 receptor or PAR2-AP. Our results demonstrated that the Arg36Ala mutation blocked, as expected, trypsin 367 activation of PAR2 without the signal peptide (Fig 7A) . However, when the PAR2-AP was used 368 as the ligand, the mutant receptor (PAR2∆SP(R36A)) demonstrated a much higher sensitivity to 369 PAR2-AP compared to that of PAR2∆SP (Fig 7B) . As a control, we made the same mutation in 370 full length PAR2 receptor (PAR2(R36A)), which responded to trypsin stimulation very poorly 371 (Fig 7B) , responded to PAR2-AP stimulation almost identically to the full length PAR2 receptor 372 (Fig 7C) . The small but detectable activation of PAR2(R36A) by trypsin (Fig 7B) could be due to 373 the cleavage of PAR2 by trypsin at Arg 31 , or Lys 34 positions, resulting in tethered ligands with 374 poor activity for receptor activation. 
383
The experiments were performed in triplicates at each data points and the results shown are mean ± sd. The experiments have been 384 performed 3 times and very similar results have been observed. Example data is shown.
386
Protease inhibitor treatment increased functional expression of PAR2 without the signal 387 peptide 388 We hypothesized that serine protease inhibitors can help the functional expression of PAR2 without 389 a signal peptide by blocking premature intracellular protease-mediated activation. A protease cocktail 390 including AEBSF, Leupeptin, and aprotinin was used to inhibit ER and Golgi proteases (16, 17). Cells 391 expressing the wild type PAR2 and various mutant forms of PAR2 were treated with the protease inhibitor 392 cocktail and then tested for their responses to PAR2-AP stimulations. Trypsin was not used in this assay 393 because it is inhibited by the protease inhibitor cocktails. Our results showed that while protease inhibitors 394 did not affect the EC 50 values of PAR2-AP stimulated responses for PAR2 wild type, PAR2(R36A),
395
PAR2∆SP(R36A), and PAR2∆SP∆L, the protease cocktail clearly increased functional expression of 396 PAR2∆SP by decreasing the EC 50 value (from 5.8 uM to 0.7 uM) (Fig 8) . To confirm whether the reduced responses of signal peptide-less PAR2 to the ligand 408 stimulation is due to a lack of total receptor protein expression, and/or a lack of cell surface 409 expression, we used a monoclonal antibody against the amino acid residues 37-62 of PAR2 in 410 ELISA assays to measure the total and cell surface expression of the various forms of PAR2 and 411 effect of protease inhibitor treatment. We observed that PAR2 wild type and PAR2(R36A) mutants 412 have the highest total and cell surface protein expression as measured by ELISA. PAR2∆SP∆L 413 has slightly lower expression compared to that of the PAR2 wild type in both total and cell surface 414 expression. As this variant of PAR2 is missing amino acid residues 1-42, its reduced detection of 415 proteins expression could be due to the poor antibody recognition. PAR2∆SP(R36A) has further 416 lower total and cell surface expression and PAR2∆SP has the lowest total and particularly cell 417 surface expression levels (Fig 9) . The data showed that the great majority of PAR2∆SP protein are 418 located intracellularly and only a small portion of it are present on the cell surface. For PAR2 wild 419 type, PAR2(R36A), and PAR2∆SP∆L, over 90% of the proteins are presented on the cell surface.
420
Corroborating the functional assays, protease inhibitor treatments increased the total and especially 421 the cell surface expression levels for PAR2∆SP while having little or no effects on the protein 422 expression of other forms of PAR2 proteins (Fig 9) . Stimulation of receptors using PAR2 peptide 423 ligand (PAR2-AP) decreased the cell surface and the total protein expression levels for all variants 424 of PAR2 except PAR2∆SP. This is likely due to that the majority of PAR2∆SP being intracellular, 425 and the ligand stimulation of the cell surface receptor, causing the subsequent internalization and 426 degradation of the stimulated receptors applies less to PAR2∆SP. 
434
In parallel, to further facilitate the measurements of the protein expression and visualization 435 of protein cellular localizations, we constructed various PAR2 expression vectors by fusing a GFP 436 tag to the C-termini of the PAR2 wild type protein and the various PAR2 mutants (Fig 10A) and 437 expressed them in the par1 and par2 null HEK293 cell line. We measured the total expression 438 levels of PAR2 and the mutant proteins by measuring GFP fluorescence intensity of the various 439 GFP fusion proteins. In general, the results are very similar to that shown by ELISA using the anti-440 PAR2 antibody except for PAR2∆SP∆L, which showed lower levels compared to that of PAR2 441 wild type in the ELISA assays, but showed similar expression levels to that of PAR2 wild type in 442 GFP intensities (Fig 10B) . This result supports our earlier speculation that the reduced detection 443 of PAR2∆SP∆L expression is likely due to the poor recognition of PAR2∆SP∆L (which misses 444 the amino acid residues 37-42 of the recognition site) by the antibody. To investigate the cellular 445 localizations of PAR2 protein and its variants, we used confocal microscopy to analyze the cells 446 that express various PAR2 proteins at various conditions including the treatments with PAR2 447 ligand or protease inhibitors. PAR2 wild type, PAR2(R36A), and PAR2∆SP∆L proteins are and little or none is on the plasma membranes, which is very similar to PAR2 wild type receptor 450 stimulated by the peptide ligand (PAR2+PAR2-AP, Fig 10C) . For PAR2∆SP(R36A), a good 451 portion of protein is expressed on the plasma membrane and a large amount of protein can also be 452 found intracellularly. Interestingly, protease inhibitor treatment enabled the plasma membrane 453 expression of PAR2∆SP (PAR2∆SP+PI, Fig 10C) . Overall, the observed GFP-tagged protein 454 cellular distribution is in agreement with the ELISA data (Fig 9) . Interestingly, the cells expressing To summarize, in this report we observed that deletion of the signal peptide of PAR2 507 decreased PAR2 cell surface expression with the most receptors accumulating intracellularly.
508
However, further deletion of the tether ligand of PAR2, which disables the activation of PAR2 by 509 trypsin, restored the receptor cell surface expression, suggesting that the necessity of the signal 510 peptide for PAR2 is related to the presence of the tether ligand sequence and the protease activation 511 mechanism. We hypothesize that the signal peptide of PAR2 protects PAR2 from intracellular 
